@entity71800 , a novel PPARy antagonist from @entity9052 , alleviates XXXX in @entity19 .

@entity407 @entity1560 @entity28 @entity19 @entity3445 @entity21244 @entity71800 @entity209 @entity9052 @entity6170
@entity28 is prevalent worldwide, and is highly associated with @entity209 , such as insulin resistance, @entity407 and @entity1560 . @entity9052 has been used as food and traditional herbal medicine for the treatment of various @entity209 . However, the molecular mechanisms how @entity9052 and its components participate in the regulation of lipogenesis are still largely unclear. Here, we identified that @entity71800 ( @entity3445 ), a major @entity9052 constituent, inhibited @entity6170 -supported adipocyte differentiation of 3T3-L1 cells by repressing the expression of lipogenesis-related gene expression. In high-fat diet-induced @entity28 (DIO) @entity19 , @entity3445 reduced body weight and serum lipid levels, improved insulin resistance, as well as morphology and lipid accumulation, @entity1560 , in the livers. These effects were confirmed with genetically @entity28 ob/ob @entity19 . A reporter gene assay showed that @entity3445 specifically inhibited the transactivity of PPARy, but not PPAR a, b/   and LXR a, b. TR-FRET assay revealed that @entity3445 was specifically bound to PPARy @entity21244 , which was further confirmed by the molecular docking study. Our data demonstrate that @entity3445 is a novel PPARy antagonist. The inhibition of PPARy activity could be a promising therapy for @entity28 and @entity1560 . Our findings shed new light on the mechanism of @entity9052 in the treatment of @entity209 .
